AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00176-08v1
52/6/2228    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Azor, M.
Right arrow Articles by Guarro, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Azor, M.
Right arrow Articles by Guarro, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2008, p. 2228-2231, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.00176-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Antifungal Susceptibility and Molecular Characterization of Clinical Isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum{triangledown}

Mónica Azor,1 Josepa Gené,1 Josep Cano,1 Deanna A. Sutton,2 Annette W. Fothergill,2 Michael G. Rinaldi,2,3 and Josep Guarro1*

Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Tarragona, Spain,1 Fungus Testing Laboratory, Department of Pathology, The University of Texas Health Science Center,2 Audie L. Murphy Memorial Veterans' Hospital, South Texas Veterans Health Care System, San Antonio, Texas3

Received 7 February 2008/ Returned for modification 6 March 2008/ Accepted 28 March 2008

A microdilution method was used to test 11 antifungal drugs against clinical isolates of Fusarium thapsinum and three different phylogenetic clades of Fusarium verticillioides that were characterized by sequencing a region of the β-tubulin gene. Terbinafine was the most-active drug against both species, followed by posaconazole against F. verticillioides.

* Corresponding author. Mailing address: Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, C/ Sant Llorenç 21, 43201 Reus, Tarragona, Spain. Phone: 34 977 759359. Fax: 34 977 759322. E-mail: josep.guarro{at}urv.cat

{triangledown} Published ahead of print on 7 April 2008.

Antimicrobial Agents and Chemotherapy, June 2008, p. 2228-2231, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.00176-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.